These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2022304)

  • 1. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine.
    Dupre J; Jenner MR; Mahon JL; Purdon C; Rodger NW; Stiller CR
    Diabetes; 1991 May; 40(5):598-604. PubMed ID: 2022304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
    Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
    Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.
    Berk MA; Clutter WE; Skor D; Shah SD; Gingerich RP; Parvin CA; Cryer PE
    J Clin Invest; 1985 Jun; 75(6):1842-51. PubMed ID: 3891786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients.
    Rakotoambinina B; Timsit J; Deschamps I; Laborde K; Jos J; Boitard C; Assan R; Robert JJ
    Diabetes Care; 1995 Nov; 18(11):1487-90. PubMed ID: 8722075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
    Hare KJ; Vilsbøll T; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus.
    Krarup T; Madsbad S; Moody AJ
    J Clin Endocrinol Metab; 1985 Jan; 60(1):120-5. PubMed ID: 3880559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic actions of alanine and terbutaline in IDDM.
    Wiethop BV; Cryer PE
    Diabetes Care; 1993 Aug; 16(8):1124-30. PubMed ID: 8375242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.
    Ross SA; Dupre J
    Diabetes; 1978 Mar; 27(3):327-33. PubMed ID: 640238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus.
    Gjessing HJ; Reinholdt B; Faber OK; Pedersen O
    Acta Endocrinol (Copenh); 1991 May; 124(5):556-62. PubMed ID: 2028714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered C-peptide/insulin molar ratios and glucose turnover rates after stimulation in nondiabetic offsprings of type II diabetic patients.
    Osei K; Holland GC
    Metabolism; 1987 Feb; 36(2):122-7. PubMed ID: 3543613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of clinical remission in recent-onset IDDM.
    Hramiak IM; Dupre J; Finegood DT
    Diabetes Care; 1993 Jan; 16(1):125-32. PubMed ID: 8422766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of beta cell failure after prolonged remission of insulin-dependent diabetes mellitus (IDDM).
    Drucker D; Zinman B
    Diabetes Care; 1984; 7(1):83-7. PubMed ID: 6423354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin.
    Assan R; Feutren G; Sirmai J; Laborie C; Boitard C; Vexiau P; Du Rostu H; Rodier M; Figoni M; Vague P
    Diabetes; 1990 Jul; 39(7):768-74. PubMed ID: 2191883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma immunoreactive somatostatin response to arginine after glycemic control with continuous subcutaneous insulin infusion in type I diabetics.
    Kobayashi T; Sawano S; Itoh T; Kosaka K
    Diabetes Care; 1987; 10(3):286-92. PubMed ID: 2885161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
    Nauck M; Stöckmann F; Ebert R; Creutzfeldt W
    Diabetologia; 1986 Jan; 29(1):46-52. PubMed ID: 3514343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.